BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 517 filers reported holding BIO-TECHNE CORP in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,108,649 | -16.9% | 192,576 | -0.3% | 0.03% | -11.4% |
| Q2 2023 | $15,765,692 | +7.8% | 193,136 | -2.0% | 0.04% | +2.9% |
| Q1 2023 | $14,627,300 | -10.5% | 197,160 | 0.0% | 0.03% | -15.0% |
| Q4 2022 | $16,340,621 | +13.9% | 197,160 | +290.3% | 0.04% | +8.1% |
| Q3 2022 | $14,346,000 | -17.6% | 50,515 | +0.5% | 0.04% | -11.9% |
| Q2 2022 | $17,418,000 | -18.6% | 50,247 | +1.7% | 0.04% | +2.4% |
| Q1 2022 | $21,387,000 | -16.5% | 49,388 | -0.3% | 0.04% | -10.9% |
| Q4 2021 | $25,616,000 | +5.4% | 49,515 | -1.3% | 0.05% | -2.1% |
| Q3 2021 | $24,313,000 | +6.0% | 50,174 | -1.5% | 0.05% | +9.3% |
| Q2 2021 | $22,929,000 | +26.9% | 50,924 | +7.7% | 0.04% | +19.4% |
| Q1 2021 | $18,062,000 | +14.0% | 47,291 | -5.2% | 0.04% | +12.5% |
| Q4 2020 | $15,849,000 | +20.8% | 49,911 | -5.7% | 0.03% | +6.7% |
| Q3 2020 | $13,116,000 | -5.9% | 52,943 | +0.3% | 0.03% | -11.8% |
| Q2 2020 | $13,933,000 | +38.7% | 52,763 | -0.4% | 0.03% | +9.7% |
| Q1 2020 | $10,049,000 | -13.2% | 52,993 | +0.5% | 0.03% | +10.7% |
| Q4 2019 | $11,579,000 | +1.8% | 52,751 | -9.2% | 0.03% | -6.7% |
| Q3 2019 | $11,372,000 | -2.7% | 58,119 | +3.7% | 0.03% | 0.0% |
| Q2 2019 | $11,684,000 | +16.1% | 56,039 | +10.6% | 0.03% | +11.1% |
| Q1 2019 | $10,064,000 | +35.3% | 50,690 | -1.4% | 0.03% | +22.7% |
| Q4 2018 | $7,440,000 | -29.5% | 51,410 | -0.6% | 0.02% | -18.5% |
| Q3 2018 | $10,558,000 | +41.8% | 51,725 | +2.8% | 0.03% | +35.0% |
| Q2 2018 | $7,446,000 | -3.1% | 50,330 | -1.1% | 0.02% | -4.8% |
| Q1 2018 | $7,683,000 | +2.8% | 50,870 | -11.8% | 0.02% | +5.0% |
| Q4 2017 | $7,471,000 | +8.1% | 57,670 | +0.9% | 0.02% | +5.3% |
| Q3 2017 | $6,913,000 | +3.4% | 57,181 | +0.5% | 0.02% | 0.0% |
| Q2 2017 | $6,686,000 | +15.8% | 56,901 | +0.2% | 0.02% | +11.8% |
| Q1 2017 | $5,774,000 | -1.3% | 56,800 | -0.1% | 0.02% | -5.6% |
| Q4 2016 | $5,849,000 | -5.9% | 56,877 | +0.2% | 0.02% | -5.3% |
| Q3 2016 | $6,214,000 | -3.9% | 56,749 | -1.0% | 0.02% | -9.5% |
| Q2 2016 | $6,465,000 | +42.7% | 57,329 | +19.6% | 0.02% | +23.5% |
| Q1 2016 | $4,531,000 | +4.3% | 47,934 | -0.7% | 0.02% | +6.2% |
| Q4 2015 | $4,346,000 | -2.7% | 48,294 | 0.0% | 0.02% | -5.9% |
| Q3 2015 | $4,465,000 | -5.9% | 48,294 | +0.2% | 0.02% | 0.0% |
| Q2 2015 | $4,744,000 | -1.8% | 48,176 | 0.0% | 0.02% | +6.2% |
| Q1 2015 | $4,832,000 | +2.8% | 48,176 | -5.3% | 0.02% | +6.7% |
| Q4 2014 | $4,700,000 | – | 50,870 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |